Vortioxetine hydrobromide troban route of elimination and binding

route of elimination and binding site on their target pancreatic β cell receptor

Preclinical studies reveal that KW-2449 is converted by monoamine oxidase-B (MAO-B) and aldehyde oxidase into its major metabolite M1

4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide dihydrochloride

Afuresertib HCl

4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S

Vortioxetine hydrobromide troban route of elimination and bindingVortioxetine, also known as Lu AA21004, is an atypical antidepressant, and was approved in 2013 by the U. S. FDA for the treatment of major depressive disorder (MDD) in adults. Vortioxetine is a so called "serotonin modulator and stimulator." It has been shown to possess the following pharmacological actions: Serotonin transporter (SERT) blocker (i. e. serotonin reuptake inhibitor (SRI)) Ki (binding affinity) = 1. 6 nM, IC50 = 5. 4 nM; Norepinephrine